Meixia Chen
Impact in
- Oncology top 1%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunology top 2%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- interferon and immune responses
Papers in
-
- Gut microbiota and health 8
- Oncology 30
- CAR-T cell therapy research 17
- Cancer Immunotherapy and Biomarkers 8
- Co-authors
- Weidong Han (35 shared papers)Kaichao Feng (15 shared papers)Yao Wang (17 shared papers)Hanren Dai (13 shared papers)Yelei Guo (12 shared papers)Qingming Yang (18 shared papers)Qian Mei (13 shared papers)Wenying Zhang (10 shared papers)
- Journals
- Journal of Clinical Oncology (7 papers)OncoImmunology (4 papers)Clinical Cancer Research (4 papers)Antioxidants (3 papers)Oncotarget (2 papers)
- Partner nations
- ChinaUnited StatesRussia
In The Last Decade
Meixia Chen
113 papers receiving 4.3k citations
Meixia Chen's Hit Papers
Peers
Comparison fields: 5 of 133
- Oncology 2.0k
- Immunology 1.2k
- Molecular Biology 1.4k
- Genetics 552
- Pathology and Forensic Medicine 283
Countries citing papers authored by Meixia Chen
This map shows the geographic impact of Meixia Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meixia Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meixia Chen more than expected).
Fields of papers citing papers by Meixia Chen
This network shows the impact of papers produced by Meixia Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meixia Chen. The network helps show where Meixia Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Meixia Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 115 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy Hit paper breakdown → | 2020 | 761 |
| 2 | 2016 | 266 | |
| 3 | 2018 | 266 | |
| 4 | 2020 | 241 | |
| 5 | 2021 | 192 | |
| 6 | 2014 | 164 | |
| 7 | 2015 | 157 | |
| 8 | 2019 | 156 | |
| 9 | 2015 | 137 | |
| 10 | 2020 | 135 | |
| 11 | 2021 | 106 | |
| 12 | 2016 | 104 | |
| 13 | Phytogenic feed additives as natural antibiotic alternatives in animal health and production: A review of the literature of the last decade Hit paper breakdown → | 2024 | 95 |
| 14 | 2018 | 75 | |
| 15 | 2022 | 61 | |
| 16 | 2023 | 54 | |
| 17 | 2014 | 50 | |
| 18 | 2021 | 49 | |
| 19 | 2015 | 47 | |
| 20 | 2017 | 45 |
About Meixia Chen
Meixia Chen is a scholar working on Molecular Biology, Oncology, Immunology, Plant Science and Pathology and Forensic Medicine, having authored 115 papers that have together received 4.3k indexed citations. Recurring topics across this work include CAR-T cell therapy research (17 papers), Immune Cell Function and Interaction (12 papers), Gut microbiota and health (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), Lymphoma Diagnosis and Treatment (7 papers), interferon and immune responses (5 papers), Reproductive System and Pregnancy (5 papers) and Probiotics and Fermented Foods (5 papers). The work is most often cited by research in Oncology (2.0k citations), Immunology (1.2k citations), Molecular Biology (1.4k citations), Genetics (552 citations) and Pathology and Forensic Medicine (283 citations). Meixia Chen has collaborated with scholars based in China, United States and Russia. Frequent co-authors include Weidong Han, Kaichao Feng, Yao Wang, Hanren Dai, Yelei Guo, Qingming Yang, Qian Mei, Wenying Zhang, Yang Liu and Chunmeng Wang. Their work appears in journals such as Journal of Clinical Oncology, OncoImmunology, Clinical Cancer Research, Antioxidants and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.